Angela Jean Rogers, MD
Critical Care (Intensivists) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Rogers’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C55968 · Current
Licensed to practise in California · since 2013 · expires 2027-02-28 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$53,290
Medicare paid this office $53,290 for 335 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 76 | $35,348 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $4,844 | $105 |
| Return visit (30+ min) | 30 | $3,141 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,271 | $67 |
| Test to examine how well the lungs exchange gases | 140 | $1,117 | $8 |
See all 8 services
| Critical care, first 30-74 minutes | 76 | $35,348 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $4,844 | $105 |
| Return visit (30+ min) | 30 | $3,141 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,271 | $67 |
| Test to examine how well the lungs exchange gases | 140 | $1,117 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 103 | $930 | $9 |
| Test to determine lung volumes using sensors | 73 | $760 | $10 |
| Test to measure expiratory airflow and volume | 92 | $665 | $7 |
Who their Medicare patients are
335 Original Medicare patients in 2024. Average age 73 · Under 65 14% · 85 and older 11% · Women 50% · Also on Medicaid 32% · Health risk score 2.63. Above the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · Coronary heart disease 41% · Chronic kidney disease 38% · COPD 37% · Heart failure 34% · Diabetes 33% · Atrial fibrillation 33% · Cancer 25% · Depression 25% · Stroke 15% · Dementia 14%.
The office billed $453,751, Medicare allowed $68,653 and paid $53,290; for 767 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 335 | 767 | 73 | 2.63 | $453,751 | $53,290 |
| 2023 | 362 | 803 | 73 | 2.21 | $476,083 | $64,745 |
| 2022 | 267 | 610 | 73 | 2.45 | $452,689 | $58,729 |
| 2021 | 251 | 631 | 73 | 2.60 | $483,329 | $64,419 |
| 2020 | 256 | 529 | 72 | 2.31 | $317,690 | $48,944 |
| 2019 | 430 | 941 | 72 | 2.14 | $311,111 | $54,009 |
| 2018 | 234 | 468 | 73 | 2.30 | $259,033 | $41,717 |
| 2017 | 242 | 552 | 71 | 2.12 | $391,871 | $57,288 |
| 2016 | 244 | 511 | 72 | 2.48 | $321,416 | $49,581 |
| 2015 | 242 | 555 | 73 | 2.53 | $316,836 | $55,109 |
| 2014 | 297 | 690 | 72 | 2.06 | $339,374 | $59,570 |
| 2013 | 144 | 437 | 72 | 2.23 | $219,139 | $44,472 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Critical care, first 30-74 minutes | 96 | $38,085 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $7,460 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $5,731 | $73 |
| Return visit (30+ min) | 36 | $3,704 | $88 |
| Test to examine how well the lungs exchange gases | 122 | $970 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 78 | $710 | $9 |
| Test to measure expiratory airflow and volume | 91 | $681 | $7 |
| Test to determine lung volumes using sensors | 53 | $558 | $11 |
2022: 9 services
| Critical care, first 30-74 minutes | 74 | $39,787 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $8,295 | $93 |
| Return visit (30+ min) | 31 | $3,194 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,763 | $65 |
| Short return visit (20+ min) | 15 | $886 | $59 |
| Test to examine how well the lungs exchange gases | 64 | $522 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 50 | $464 | $9 |
| Test to measure expiratory airflow and volume | 55 | $423 | $8 |
| Test to determine lung volumes using sensors | 30 | $320 | $11 |
2021: 10 services
| Critical care, first 30-74 minutes | 74 | $43,531 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $8,687 | $95 |
| Return visit (30+ min) | 32 | $3,248 | $90 |
| Critical care, each additional 30 minutes | 15 | $1,602 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $996 | $66 |
| Short return visit (20+ min) | 12 | $791 | $66 |
| Test to examine how well the lungs exchange gases | 76 | $617 | $8 |
| Test to measure expiratory airflow and volume | 58 | $439 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 43 | $386 | $9 |
| Test to determine lung volumes using sensors | 29 | $316 | $11 |
2020: 9 services
| Critical care, first 30-74 minutes | 63 | $33,393 | $202 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,509 | $94 |
| Return visit (30+ min) | 37 | $2,548 | $61 |
| New patient visit (45+ min) | 14 | $1,676 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,074 | $67 |
| Test to examine how well the lungs exchange gases | 62 | $406 | $6 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 42 | $404 | $10 |
| Test to measure expiratory airflow and volume | 61 | $388 | $6 |
| Test to determine lung volumes using sensors | 24 | $208 | $9 |
2019: 9 services
| Critical care, first 30-74 minutes | 57 | $28,321 | $198 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $7,924 | $94 |
| Return visit (30+ min) | 44 | $3,732 | $70 |
| New patient visit (45+ min) | 19 | $2,212 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $1,848 | $66 |
| Test to examine how well the lungs exchange gases | 190 | $1,616 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 114 | $1,380 | $12 |
| Test to measure expiratory airflow and volume | 155 | $1,218 | $8 |
| Test to determine lung volumes using sensors | 86 | $994 | $11 |
2018: 10 services
| Critical care, first 30-74 minutes | 52 | $23,714 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $6,553 | $94 |
| Return visit (30+ min) | 39 | $2,604 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,589 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,438 | $65 |
| New patient visit (45+ min) | 12 | $1,160 | $97 |
| Test to examine how well the lungs exchange gases | 51 | $419 | $8 |
| Test to measure expiratory airflow and volume | 44 | $334 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 26 | $307 | $12 |
| Test to determine lung volumes using sensors | 18 | $200 | $11 |
2017: 10 services
| Critical care, first 30-74 minutes | 65 | $40,885 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $6,076 | $93 |
| Return visit (30+ min) | 33 | $2,097 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,296 | $65 |
| Short return visit (20+ min) | 11 | $456 | $41 |
| Test to examine how well the lungs exchange gases | 54 | $432 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $377 | $11 |
| Test to determine lung volumes using sensors | 25 | $266 | $11 |
| Test to measure expiratory airflow and volume | 29 | $219 | $8 |
| Test to measure expiratory airflow and volume | 21 | $152 | $7 |
2016: 9 services
| Critical care, first 30-74 minutes | 62 | $31,113 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $7,037 | $93 |
| Return visit (30+ min) | 34 | $2,451 | $70 |
| New patient visit (45+ min) | 15 | $1,730 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $772 | $64 |
| Test to examine how well the lungs exchange gases | 61 | $499 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $388 | $12 |
| Test to determine lung volumes using sensors | 26 | $288 | $11 |
| Test to measure expiratory airflow and volume | 37 | $281 | $8 |
2015: 11 services
| Critical care, first 30-74 minutes | 67 | $31,214 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $9,111 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,893 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,132 | $61 |
| Return visit (30+ min) | 20 | $1,542 | $70 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,339 | $122 |
| Hospital discharge day management, 30 minutes or less | 12 | $794 | $66 |
| Test to examine how well the lungs exchange gases | 53 | $401 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | $383 | $11 |
| Test to determine lung volumes using sensors | 23 | $239 | $10 |
| Test to measure expiratory airflow and volume | 32 | $220 | $7 |
2014: 9 services
| Critical care, first 30-74 minutes | 73 | $34,989 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $5,508 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $4,621 | $92 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,921 | $122 |
| Return visit (30+ min) | 27 | $1,882 | $65 |
| Test to examine how well the lungs exchange gases | 92 | $772 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 51 | $594 | $12 |
| Test to measure expiratory airflow and volume | 57 | $439 | $8 |
| Test to determine lung volumes using sensors | 34 | $376 | $11 |
2013: 9 services
| Critical care, first 30-74 minutes | 39 | $28,891 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $4,953 | $59 |
| Diagnostic exam of lung airway using an endoscope | 11 | $2,422 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,056 | $114 |
| Return visit (30+ min) | 18 | $1,218 | $68 |
| Test to examine how well the lungs exchange gases | 36 | $304 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 19 | $218 | $11 |
| Test to measure expiratory airflow and volume | 27 | $193 | $7 |
| Test to determine lung volumes using sensors | 13 | $150 | $12 |
Medicaid work
$5,886 in 2024
Medicaid paid $5,886 for 139 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 80 | $5,524 |
| EVALUATION OF WHEEZING | 17 | $192 |
| Diffusing capacity | 42 | $170 |
| 2024 | 139 | 3 | 19 | $5,886 |
| 2023 | 66 | 3 | 16 | $4,365 |
| 2022 | 29 | 1 | 15 | $200 |
| 2020 | 168 | 2 | 23 | $14,769 |
| 2019 | 124 | 5 | 22 | $2,339 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 24 | $4,170 |
| Diffusing capacity | 29 | $110 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 13 | $85 |
2022
| Diffusing capacity | 29 | $200 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 155 | $14,657 |
| Diffusing capacity | 13 | $112 |
2019
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 20 | $1,426 |
| EVALUATION OF WHEEZING | 44 | $576 |
| Diffusing capacity | 34 | $183 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 14 | $81 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 12 | $74 |
Drugs they prescribed that Part D paid
$17,849
Pharmacies billed $17,849 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 110) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
44 generic and 66 brand-name prescriptions · $17,849 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Breo Ellipta | 16 | $6,314 | $395 |
| Albuterol Sulfate Hfa | 31 | $1,220 | $39 |
Year by year
| 2024 | 110 | 21 | 0% (0) | 60% | $17,849 |
| 2023 | 87 | 16 | 0% (0) | 57% | $24,814 |
| 2022 | 83 | 12 | 0% (0) | 71% | $27,695 |
| 2021 | 76 | 13 | 0% (0) | 62% | $26,234 |
| 2020 | 69 | 19 | 0% (0) | 51% | $25,275 |
| 2019 | 96 | 34 | 0% (0) | 75% | $21,464 |
| 2018 | 167 | 35 | 0% (0) | 72% | $55,848 |
| 2017 | 206 | 50 | 0% (0) | 47% | $51,336 |
| 2016 | 156 | 39 | 0% (0) | 36% | $19,058 |
| 2015 | 78 | 28 | 0% (0) | 49% | $6,365 |
| 2014 | 51 | 18 | 0% (0) | 59% | $7,542 |
| 2013 | 13 | None | 0% (0) | None | $1,584 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Breo Ellipta | 13 | $7,369 | $567 |
| Albuterol Sulfate Hfa | 23 | $979 | $43 |
2022: 3 drugs
| Spiriva Handihaler | 13 | $8,202 | $631 |
| Breo Ellipta | 13 | $5,533 | $426 |
| Ventolin Hfa | 12 | $765 | $64 |
2021: 2 drugs
| Advair Diskus | 11 | $6,983 | $635 |
| Breo Ellipta | 12 | $4,788 | $399 |
2020: 2 drugs
| Atovaquone | 11 | $10,793 | $981 |
| Wixela Inhub | 13 | $2,066 | $159 |
2019: 1 drug
| Ventolin Hfa | 12 | $698 | $58 |
2018: 5 drugs
| Spiriva | 21 | $13,810 | $658 |
| Symbicort | 17 | $13,129 | $772 |
| Advair Diskus | 12 | $5,476 | $456 |
| Ventolin Hfa | 11 | $943 | $86 |
| Azithromycin | 16 | $682 | $43 |
2017: 7 drugs
| Spiriva | 23 | $14,250 | $620 |
| Advair Diskus | 17 | $7,473 | $440 |
| Symbicort | 13 | $6,539 | $503 |
| Proair Hfa | 12 | $688 | $57 |
| Azithromycin | 17 | $649 | $38 |
| Montelukast | 19 | $305 | $16 |
| Fluticasone Propionate | 12 | $176 | $15 |
2016: 5 drugs
| Advair Diskus | 12 | $4,223 | $352 |
| Rifampin | 14 | $422 | $30 |
| Montelukast | 14 | $271 | $19 |
| Azithromycin | 14 | $164 | $12 |
| Fluticasone Propionate | 11 | $157 | $14 |
2015: 1 drug
| Proair Hfa | 14 | $704 | $50 |
2014: 1 drug
| Proair Hfa | 14 | $679 | $49 |
Money from drug and device companies
$15 in 2025
| 2025 | 1 | 1 | None | $15 |
| 2021 | 1 | 2 | $3,575 | $3,575 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medline Industries LP | None | $15 | 1 payment
|
See the published payment
| Medline Industries LP | Meals · 2025-05-01 | None | $15 |
See earlier years (2021)
2021: $3,575
| Merck Sharp & Dohme | None | $3,575 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1922179159
- Licence
- CA C55968California C55968: Current · expires 2027-02-28
- Trained
- Harvard Medical School, 2001
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-11-10
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2690 Hanover St, Palo Alto, CA, 94304